• RXRX is trading 4% down today at $3.69, impacted by a recent SEC filing (Form 144 dated July 7, 2026) signaling planned insider share sales by CEO Christopher Gibson.
  • The selloff also reflects fading gains from its recent Russell index inclusion, broader market downturn, and investors reassessing risk for AI-driven drug discovery companies.
  • This comes despite the company's Q1 2026 earnings beating analyst expectations in May.